NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing lifesaving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the appointment of Dr. Thomas R. Zimmerman Jr. as its Vice President, Medical Affairs.
“Dr. Zimmerman’s deep passion for leveraging breakthroughs in science to save and improve patients’ lives – which is completely in line with Remedy’s stated mission and core values – makes him an ideal addition to the senior management team,” states Sven Jacobson, CEO of Remedy Pharmaceuticals. “His extensive experience in clinical drug development and deep knowledge of the regulatory environment are certain to prove invaluable as we prepare to enter a Phase 3 clinical trial for CIRARA, and beyond.”
Thomas R. Zimmerman Jr., MD, F.A.A.N, has over 30 years of medical experience as well as 25 years in clinical drug development, having been an integral part of five New Drug Applications and four commercial drug launches. He has lead 18 acute neurology studies, and has consulted with over 30 companies including Wyeth, now part of Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Biogen (NASDQ:BIIB), and Teva (NYSE:TEVA). Prior to his consulting work, Dr. Zimmerman was the Chief Medical Officer & Vice President of Research and Development at Daiichi Asubio Pharmaceuticals, and the Vice President, Medical Affairs at Yamanouchi Pharmaceuticals. He is the author of over 50 scientific publications and has lectured at the Columbia University School of Medicine as well as Johns Hopkins Center for Biotechnology. Dr. Zimmerman received his B.A. in Biophysics from the Johns Hopkins University and his MD from the University of Medicine and Dentistry of New Jersey in 1986, where he continues to teach as adjunct faculty.
“I am honored to join the team during this truly exciting time in Remedy’s history,” said Dr. Zimmerman. “Joining Remedy offers an incredible opportunity to play a pivotal role in bringing an exciting drug to market while working to accelerate Remedy’s diversified efforts in other CNS-related conditions, such as spinal cord injury, traumatic brain injury, and subarachnoid hemorrhage.”
CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.